Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Fineline Cube Apr 10, 2026
Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Fineline Cube Apr 10, 2026
Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026
Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Fineline Cube Apr 10, 2026
Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Fineline Cube Apr 10, 2026
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025

Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non‑exclusive licensing agreement with EirGenix...

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...

Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025

Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy,...

Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025

China’s National Medical Products Administration (NMPA) published the 2025 Edition of the Directory of High-End...

Company Medical Device

Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU

Fineline Cube Dec 29, 2025

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that it has submitted the registration application for...

Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025

TJ Biopharma announced a strategic cooperation agreement with Zhejiang Lab Technology Holdings Co., Ltd. (Zhike...

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQH3906, a Category 1 innovative oral TYK2/JAK1 inhibitor, has...

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025

HBM Holdings Limited (HKG: 2142) announced a long‑term strategic collaboration with Yantai Lannacheng Biotechnology Co.,...

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025

Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience...

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025

AstraZeneca PLC (AZ, NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) announced that Wainua (eplontersen) has received approval...

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025

AstraZeneca PLC (AZ, NASDAQ: AZN) announced that Fasenra (benralizumab) has received additional approval from China’s...

Company Drug

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

Fineline Cube Dec 29, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Medical Device

Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China

Fineline Cube Dec 29, 2025

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its Human Immunodeficiency Virus...

Company Drug

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Fineline Cube Dec 29, 2025

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that furmonertinib has been added to the Breakthrough...

Company Medical Device

UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio

Fineline Cube Dec 29, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG: 2252) announced that its self‑developed UniPath Electronic Bronchoscopic...

Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Fineline Cube Dec 29, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that China’s National Medical Products Administration (NMPA) accepted...

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Fineline Cube Dec 29, 2025

Novo Nordisk (NYSE: NVO) announced that its once‑weekly long‑acting growth hormone (LAGH) injection, Sogroya (somapacitan), received...

Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Fineline Cube Dec 29, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Amivantamab Injection (Subcutaneous), marketed as RYBREVANT, received...

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025

Hybio Pharmaceutical and Dr. Reddy’s Laboratories entered a strategic partnership, signing a non‑binding Term Sheet...

Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025

The National Development and Reform Commission (NDRC) issued the “Catalogue of Industries Encouraging Foreign Investment...

Posts pagination

1 … 46 47 48 … 648

Recent updates

  • C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
  • Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis
  • Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K
  • Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia
  • BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.